OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

On Monday, three logos were revealed to the public, one for each potential nickname, but NHL fans weren't particularly impressed by the latest round of options. Much of the criticism was focused ...

Vertex’s quest to treat a wider group of patients with cystic fibrosis (CF) continues after the FDA approved its latest combination therapy, Symdeko. Symdeko adds the new component of tezacaftor ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

However, higher Trikafta/Kaftrio sales are likely to have caused sales erosion of Vertex’s other CF drugs — Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. Vertex and partner CR ...

It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF ...

“Unfortunately, Brett was diagnosed with thyroid cancer toward the end of last year, around our one-year wedding anniversary,” she said in a confessional. “I thought, like, how? Like, I’m ...

It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF ...